Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880157 | 0.86 | KDM4E (0.51) | KDM4EPKMPIK3CAPRKDCBRD4 | |
| SCHEMBL17063253 | 0.82 | FPR2 (0.48) | FPR2USP30KDM4EPKMKRAS | |
| SCHEMBL7712492 | 0.80 | FPR2 (0.49) | FPR2USP30KDM4EPKMKRAS | |
| SCHEMBL6150400 | 0.79 | KDM4E (0.54) | FPR2KDM4EPKMGPR119MAPT | |
| SCHEMBL1333790 | 0.79 | CNR2 (0.56) | P2RX3 | |
| SCHEMBL17063375 | 0.77 | POLB (0.48) | KDM4EKRASMAPTP2RX3 | |
| SCHEMBL6521790 | 0.74 | FPR2 (0.42) | FPR2KDM4EKRASPIK3CAPRKDC | |
| SCHEMBL14744932 | 0.74 | USP30 (0.56) | FPR2USP30KDM4EGPR119FPR3 | |
| SCHEMBL26151149 | 0.74 | FPR2 (0.47) | FPR2USP30KDM4EPKMGPR119 | |
| SCHEMBL31108104 | 0.74 | FPR2 (0.51) | FPR2KDM4EPKMGPR119FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116504-A2 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138276-A2 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RARG | FPR2 2671/4885USP30 2085/4885KDM4E 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.